Health Trials

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

ConditionSmall Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd

About this trial

This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.

Eligibility criteria

Qualifiers

Participants with histologically or cytologically confirmed ES-SCLC.

Fully understand the study and voluntarily sign the informed consent form;

Male or female 18~75 years of age;

Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;

Disqualifiers

Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Trial design

Treatments tested in this trial

  • ZG006
  • Serplulimab

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Lead sponsor

Source ClinicalTrials.gov